> 首页 > 产品 > 一抗 > 其他 > Anti-HER3 & IGF-1R Reference Antibody (Istiratumab)

Anti-HER3 & IGF-1R Reference Antibody (Istiratumab)

Anti-HER3 & IGF-1R Reference Antibody (Istiratumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-HER3 & IGF-1R Reference Antibody (Istiratumab) is 95.55 %, determined by SEC-HPLC.
Istiratumab bound to 4-1BB protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Istiratumab bound to Human IGF-1R-His, and the EC50 was 0.022 nM.
Istiratumab bound to HER3 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Istiratumab bound to Human HER3-His, and the EC50 was 0.046 nM.
Istiratumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Istiratumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and the EC50 was 1.257 nM.
The detected molecular weight of Anti-HER3 & IGF-1R Reference Antibody (Istiratumab) is 199.64 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P21860 & P08069
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information
Target/Specificity	ERBB3 / HER3,IGF1-R / IGFR1 / CD221
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.